Chris Calabrese | Investor Relations |
Steven Shallcross | Chief Executive and Chief Financial Officer |
Manel Cascalló | General Director, Theriva Biologics Europe |
Frank Tufaro | Chief Operating Officer |
Vince Wacher | Head, Corporate and Product Development |
Jim Molloy | Alliance Global Partners |
Good day and welcome to the Theriva Biologics formerly Synthetic Biologics 2022 Third Quarter Operational Highlights and Financial Results. Today’s conference is being recorded. At this time, I would like to turn the conference over to Mr. Chris Calabrese, LifeSci Advisors Relationship Manager. Please go ahead, sir.